PMID- 14741762
OWN - NLM
STAT- MEDLINE
DCOM- 20040503
LR  - 20190901
IS  - 0165-3806 (Print)
IS  - 0165-3806 (Linking)
VI  - 147
IP  - 1-2
DP  - 2003 Dec 30
TI  - Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and 
      serotonin neurochemistry and increases brain-derived neurotrophic factor in the 
      forebrain and brainstem of the rat.
PG  - 177-82
AB  - Growing concerns surround the risk of fetal exposure to 
      3,4-methylenedioxymethamphetamine (MDMA; ecstasy). Prior animal studies using 
      neonatal rats administered MDMA from postnatal days (P) 11-20 (a period 
      approximating third trimester brain development in humans) have demonstrated 
      long-lasting decrements in serotonin (5-HT) and learning; however, no studies 
      have examined the acute post-MDMA response of the brain at this early age. 
      Specifically, it is of interest whether MDMA administration to neonatal rats 
      produces the expected depletion of monoamines and whether the brain exhibits any 
      ameliorative response to the pharmacologic insult. In the current study, this 
      model was employed to determine whether forebrain and brainstem dopamine (DA) and 
      5-HT neurochemistry were altered 24 h after the last injection (P21), and whether 
      brain-derived neurotrophic factor (BDNF) was upregulated in response to MDMA 
      exposure. All forebrain structures examined (frontal cortex, hippocampus, and 
      striatum) showed significant MDMA-induced reductions in 5-HT and its metabolite, 
      5-HIAA, and significant increases in the DA metabolite, HVA, as well as DA 
      turnover (HVA/DA). In the brainstem, there were significant increases in 5-HIAA, 
      HVA and DA turnover. BDNF was significantly increased (19-38%) in all forebrain 
      structures and in the brainstem in MDMA-exposed neonates versus saline controls. 
      These data suggest that MDMA exposure to the developing rat brain from P11-20 
      produces similar alterations in serotonin and dopamine neurochemistry to those 
      observed from adult administrations. In addition, a compensatory increase in BDNF 
      was observed and may be the brains ameliorative response to minimize MDMA 
      effects. This is the first report demonstrating that MDMA exposure results in 
      increased levels of BDNF and that such increases are correlated with changes in 
      monoamine levels. Future research is needed to elucidate any deleterious effects 
      MDMA-induced increases in trophic activity might have on the developing brain and 
      to examine earlier gestational exposure periods in order to assess the risk 
      throughout pregnancy.
FAU - Koprich, James B
AU  - Koprich JB
AD  - Department of Neurological Sciences, Rush University, Rush-Presbyterian-St. 
      Luke's Medical Center, 1735 W. Harrison Street, Suite 265, Chicago, IL 60612, 
      USA.
FAU - Campbell, Nicholas G
AU  - Campbell NG
FAU - Lipton, Jack W
AU  - Lipton JW
LA  - eng
GR  - R01 DA12624/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Brain Res Dev Brain Res
JT  - Brain research. Developmental brain research
JID - 8908639
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Hallucinogens)
RN  - 333DO1RDJY (Serotonin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Animals, Newborn/*physiology
MH  - Brain Chemistry/*drug effects
MH  - Brain Stem/drug effects/*metabolism
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Dopamine/*metabolism
MH  - Female
MH  - Frontal Lobe/drug effects/metabolism
MH  - Hallucinogens/*toxicity
MH  - Hippocampus/drug effects/metabolism
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*toxicity
MH  - Neostriatum/drug effects/metabolism
MH  - Pregnancy
MH  - Prosencephalon/drug effects/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/*metabolism
MH  - Weight Gain/drug effects
EDAT- 2004/01/27 05:00
MHDA- 2004/05/05 05:00
CRDT- 2004/01/27 05:00
PHST- 2004/01/27 05:00 [pubmed]
PHST- 2004/05/05 05:00 [medline]
PHST- 2004/01/27 05:00 [entrez]
AID - S0165380603002190 [pii]
AID - 10.1016/s0165-3806(03)00219-0 [doi]
PST - ppublish
SO  - Brain Res Dev Brain Res. 2003 Dec 30;147(1-2):177-82. doi: 
      10.1016/s0165-3806(03)00219-0.